Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AVROBIO, Inc.
Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.
Avrobio dropping out of the race means Sangamo can take advantage but its gene therapy must show long-term efficacy in patients not receiving enzyme replacement therapy.
A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.
- Drug Delivery
In Vitro Diagnostics
- Therapeutic Drug Monitoring
- Gene Therapy, Cell Therapy
- Large Molecule